Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX in Resectable Pancreatic Adenocarcinoma
NCT01660711Phase 2Completed
- Sponsor
- Endeavor Health
- Start
- Jul 2012
- Primary completion
- Aug 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin in pancreatic adenocarcinoma (PDAC), sponsored by Endeavor Health. Started Jul 2012; status: completed.
02
Drugs
fluorouracilfolinic acidirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01660711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01660711.